Michelangelo - Oasis 5

PHASE3CompletedINTERVENTIONAL
Enrollment

20,078

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Thromboembolism
Interventions
DRUG

Fondaparinux

fondaparinux 2.5 mg, s.c. injection once daily x 8 days or Hospital Discharge if earlier and placebo-enoxaparin 1mg/kg s.c. injection twice daily x 2-8 days or until clinically stable

DRUG

enoxaparin

enoxaparin 1mg/kg s.c. injection twice daily x 2 to 8 days

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

University of Chicago

OTHER

collaborator

Organon

INDUSTRY

collaborator

Sanofi

INDUSTRY

collaborator

Duke University

OTHER

lead

GlaxoSmithKline

INDUSTRY